transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial

Författare och institution:
P. Hoever (-); G. Dorffner (-); H. Benes (-); T. Penzel (-); H. Danker-Hopfe (-); M. J. Barbanoj (-); G. Pillar (-); B. Saletu (-); O. Polo (-); D. Kunz (-); J. Zeitlhofer (-); S. Berg (-); M. Partinen (-); C. L. Bassetti (-); B. Hogl (-); I. O. Ebrahim (-); E. Holsboer-Trachsler (-); H. Bengtsson (-); Yüksel Peker (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); U. M. Hemmeter (-); E. Chiossi (-); G. Hajak (-); J. Dingemanse (-)
Publicerad i:
Clinical pharmacology and therapeutics, 91 ( 6 ) s. 975-985
ISSN:
1532-6535
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2012
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double-blind, randomized, placebo-controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1-week intervals. The primary end point was sleep efficiency (SE) measured by polysomnography; secondary end points were objective latency to persistent sleep (LPS), wake after sleep onset (WASO), safety, and tolerability. Dose-dependent almorexant effects were observed on SE, LPS, and WASO. SE improved significantly after almorexant 400 mg vs. placebo (mean treatment effect 14.4%; P < 0.001). LPS (-18 min (P = 0.02)) and WASO (-54 min (P < 0.001)) decreased significantly at 400 mg vs. placebo. Adverse-event incidence was dose-related. Almorexant consistently and dose-dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin
Postens nummer:
157891
Posten skapad:
2012-05-22 14:46
Posten ändrad:
2016-06-10 11:52

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007